{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-048968","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2022-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.805264+00:00","generated_at":"2026-06-26T05:24:04.860189+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Mustang Bio appoints Eliot M. Lurier as Interim CFO via Danforth Advisors","bullets":["Eliot M. Lurier, age 63, appointed Interim CFO effective April 18, 2022; he is a consultant from Danforth Advisors.","Lurier will serve as principal financial officer under a consulting agreement with Danforth; he receives no direct compensation from Mustang.","Prior to Danforth, Lurier was CFO of Joslin Diabetes Center (2014-2020); he holds a B.S. in Accounting and is a CPA.","No family relationships or transactions requiring disclosure exist between Lurier and Mustang's directors or officers."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-048968","json":"https://secwatch.observer/filing/0001104659-22-048968.json","markdown":"https://secwatch.observer/filing/0001104659-22-048968.md","text":"https://secwatch.observer/filing/0001104659-22-048968.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000110465922048968/0001104659-22-048968-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000110465922048968/tm2213050d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:24:04.860189+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d63461db60","claim":"Eliot M. Lurier was appointed as Interim Chief Financial Officer at MUSTANG BIO, INC..","evidence_excerpt":"On April 18, 2022, Mustang Bio, Inc. (the “Company”) appointed Eliot M. Lurier as the Company’s Interim Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680048/000110465922048968/0001104659-22-048968-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}